Britain’s medicines regulator said on Friday that it has approved the use of the Pfizer/BioNTech CCP virus vaccine in 12 to 15-year-olds. The Medicines and Healthcare products Regulatory Agency (MHRA) said the decision follows a “rigorous review” of safety and effectiveness in that age group. Dr. June Raine, MHRA chief executive, said: “We have carefully reviewed clinical trial data in children aged 12 to 15 years and have concluded that the Pfizer/BioNTech COVID-19 vaccine is safe and effective in this age group and that the benefits of this vaccine outweigh any risk. “We have in place a comprehensive safety surveillance strategy for monitoring the safety of all UK-approved COVID-19 vaccines and this surveillance will include the 12- to 15-year age group. “No extension to an authorisation would be approved unless the expected standards of safety, quality, and effectiveness have been met. “It will now be for the Joint Committee on …